Baranda Ana B, Alonso Rosa M, Jiménez Rosa M, Weinmann Wolfgang
Departamento de Química Analítica, Facultad de Ciencia y Tecnología, Universidad del País Vasco/EHU, Apdo. 644, E-48080 Bilbao, Spain.
Forensic Sci Int. 2006 Jan 6;156(1):23-34. doi: 10.1016/j.forsciint.2004.11.014.
1,4-Dihydropyridines calcium channel antagonists (1,4-DHP CCAs) are photolabile and the products of their photodecomposition have no pharmaceutical activity. In our previous work we have presented a screening procedure for eleven 1,4-DHPs in plasma by LC-MS-MS using multiple reaction motoring. The laboratory process includes preparation and storage of stock solutions, plasma storage, solid-phase extraction, reconstitution of extracts and storage time in an autosampler for LC-MS-MS analysis. Prior to validation of the analytical procedure, we have tested the stability of these compounds by exposure to light. Methanolic solutions have been exposed to laboratory and UV light and the stability of the compounds in plasma was tested by exposure of spiked plasma samples to laboratory light at room temperature. Stability during freeze-thaw cycles and stability during 2 month storage at -20 degrees C have been tested as well. Products of photodecomposition have been identified after forced degradation and the degree of degradation has been quantified using LC-UV-DAD and LC-MS-MS, respectively. A 96% degradation after only 2h has been observed when solutions of nifedipine or nisoldipine were exposed to laboratory light in clear glass vials. In plasma samples degradation was 25% in only 2h for both compounds. The main degradation product was produced by oxidation of the dihydropyridinic ring resulting in the pyridine analogue that has been described as the first metabolite in the metabolic pathway. Only minor degradation was found for the other tested compounds after 2h light exposure in methanolic solutions. Furthermore, lercanidipine and nicardipine were also degradated by esterhydrolysis. Several additional minor degradation products were found for the other tested 1,4-DHPs, however, some of them could not be identified. Preconditions for storage and handling of plasma samples prior to and during analysis for 1,4-DHP CCAs are suggested in order to avoid photodecomposition of the analytes.
1,4-二氢吡啶类钙通道拮抗剂(1,4-DHP CCA)具有光不稳定的特性,其光解产物无药理活性。在我们之前的工作中,我们提出了一种通过液相色谱-串联质谱(LC-MS-MS)采用多反应监测法对血浆中的11种1,4-二氢吡啶类化合物进行筛查的程序。实验室流程包括储备液的制备和储存、血浆储存、固相萃取、提取物的复溶以及在自动进样器中用于LC-MS-MS分析的储存时间。在验证分析程序之前,我们通过光照测试了这些化合物的稳定性。甲醇溶液已暴露于实验室光和紫外光下,并且通过将加标血浆样品在室温下暴露于实验室光来测试化合物在血浆中的稳定性。还测试了冻融循环期间的稳定性以及在-20℃下储存2个月期间的稳定性。在强制降解后已鉴定出光解产物,并分别使用LC-UV-DAD和LC-MS-MS对降解程度进行了定量。当硝苯地平或尼索地平溶液在透明玻璃瓶中暴露于实验室光下时,仅2小时后就观察到96%的降解。对于这两种化合物,血浆样品中仅2小时的降解率就达25%。主要降解产物是由二氢吡啶环氧化产生的吡啶类似物,该吡啶类似物被描述为代谢途径中的第一种代谢物。在甲醇溶液中光照2小时后,其他测试化合物仅发现轻微降解。此外,乐卡地平与尼卡地平也会发生酯水解降解。对于其他测试的1,4-二氢吡啶类化合物还发现了几种额外的次要降解产物,然而,其中一些无法鉴定。为避免分析物的光解,建议了在分析1,4-DHP CCA之前及分析期间血浆样品储存和处理的前提条件。